Tildrakizumab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Source | Humanized (from mouse) |
Target | IL23 |
Clinical data | |
Legal status | ? |
Identifiers | |
CAS number | 1326244-10-3 |
ATC code | None |
Chemical data | |
Formula | C6426H9918N1698O2000S46 |
Mol. mass | 144.4 kDa |
Tildrakizumab is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[1]
This drug was developed by Merck Sharp & Dohme Corp.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Tildrakizumab, American Medical Association.
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.